RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation

Cancer Research

Volumn 65, Issue 23, 2005, Pages 11034-11043

  Glunde, Kristine ^a   Raman, Venu ^a   Mori, Noriko ^a   Bhujwalla, Zaver M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHOLINE KINASE; CYCLINE; GALECTIN 3; KI 67 ANTIGEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOGENESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; TARGET CELL;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHOLINE; CHOLINE KINASE; DOWN-REGULATION; HUMANS; MAGNETIC RESONANCE IMAGING; PHOSPHOLIPIDS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 28244464886     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1807     Document Type: Article

References (60)

1. Ramirez de Molina A, Gutierrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002;21:4317-22.
2. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R. et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296: 580-3.
3. de Molina AR, Banez-Coronel M, Gutierrez R, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004;64: 6732-9.
4. Nakagami K, Uchida T, Ohwada S, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res 1999;90: 419-24.
5. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Morishita Y. Increased choline kinase activity in 1,2-dimethylhydrazine-induced rat colon cancer. Jpn J Cancer Res 1999;90:1212-7.
6. Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995;323: 313-22.
7. Teegarden D, Taparowsky EJ, Kent C. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. J Biol Chem 1990; 265:6042-7.
8. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002; 21:937-46.
9. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001;84:691-6.
10. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 1999;59: 3112-8.
11. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413-39.
12. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-24.
13. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003;90:525-33.
14. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001; 3:36-40.
15. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 1992;5: 226-33.
16. Ting YL, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 1996; 16:1381-8.
17. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59: 80-4.
18. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
19. Ramirez de Molina A, Rodriguez-Gonzalez A, Penalva V, Lucas L, Lacal JC. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-,and N-ras-transformed cells. Biochem Biophys Res Commun 2001;285:873-9.
20. Hernandez-Alcoceba R, Saniger L, Campos J, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15:2289-301.
21. Warden CH, Friedkin M. Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J Biol Chem 1985;260:6006-11.
22. Vigo C, Vance DE. Effect of diethylstilboestrol on phosphatidylcholine biosynthesis and choline metabolism in the liver of roosters. Biochem J 1981;200:321-6.
23. Pelech SL, Vance DE. Regulation of phosphatidylcholine biosynthesis. Biochim Biophys Acta 1984;779: 217-51.
24. Uchida T. Stimulation of phospholipid synthesis in HeLa cells by epidermal growth factor and insulin: activation of choline kinase and glycerophosphate acyltransferase. Biochim Biophys Acta 1996;1304:89-104.
25. Jimenez B, del Peso L, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 1995;57:141-9.
26. Ko KW, Cook HW, Vance DE. Reduction of phosphatidylcholine turnover in a Nb 2 lymphoma cell line after prolactin treatment. A novel mechanism for control of phosphatidylcholine levels in cells. J Biol Chem 1986;261: 7846-52.
27. Neeman M, Degani H. Early estrogen-induced metabolic changes and their inhibition by actinomycin D and cycloheximide in human breast cancer cells: 3IP and 13C NMR studies. Proc Natl Acad Sci U S A 1989;86: 5585-9.
28. Chung T, Huang JS, Mukherjee JJ, Crilly KS, Kiss Z. Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. Cell Signal 2000;12: 279-88.
29. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 2004;43:266-81.
30. Campos JM, Nunez MC, Sanchez RM, et al. Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg Med Chem 2002;10:2215-31.
31. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431: 371-8.
32. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A 2002;99:1443-8.
33. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58.
34. Paine TM, Soule HD, Pauley RJ, Dawson PJ. Characterization of epithelial phenotypes in mortal and immortal human breast cells. Int J Cancer 1992; 50:463-73.
35. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
36. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 2003;5:533-45.
37. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy, Magn Reson Med 1996;35:194-200.
38. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985;100:965-73.
39. Greenspan P, Fowler SD. Spectrofluorometric studies of the lipid probe, Nile red. J Lipid Res 1985;26:781-9.
40. Fukumoto S, Fujimoto T. Deformation of lipid droplets in fixed samples. Histochem Cell Biol 2002; 118:423-8.
41. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001; 61:2945-52.
42. Guilbaud NF, Gas N, Dupont MA, Valette A. Effects of differentiation- inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 1990; 145:162-72.
43. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 2001;7: 661-8.
44. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2004;19:543-9.
45. May GL, Wright LC, Holmes KT, et al. Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. J Biol Chem 1986;261:3048-53.
46. Heimann R, Hellman S. Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer 2000;36:1631-9.
47. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003;116:3051-60.
48. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
49. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-12.
50. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, lacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000;6:1389-93.
51. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993;8:2959-68.
52. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-203.
53. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003 Dec;170(6 Pt 2):S69-75; discussion S75-6.
54. Mather IH, Keenan TW. Origin and secretion of milk lipids. J Mammary Gland Biol Neoplasia 1998;3: 259-73.
55. Jensen RG, Ferris AM, Lammi-Keefe CJ. Lipids in human milk; and infant formulas. Annu Rev Nutr 1992; 12:417-41.
56. Bell RM, Coleman RA. Enzymes of glycerolipid synthesis in eukaryotes. Annu Rev Biochem 1980;49: 459-87.
57. Lehner R, Kuksis A. Biosynthesis of triacylglycerols. Prog Lipid Res 1996;35:169-201.
58. Delikatny EJ, Roman SK, Hancock R, et al. Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Int J Cancer 1996;67:72-9.
59. Sathasivam N, Brammah S, Wright LC, Delikatny EJ. Inhibition of tetraphenylphosphonium-induced NMR-visible lipid accumulation in human breast cells by chlorpromazine. Biochim Biophys Acta 2003;1633: 149-60.
60. Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res 2002;62:1394-400.